EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CYP2D6 Metabolizer Phenotype Is Associated with Early Antidepressant Discontinuation in the UK Biobank

Tehila Cohen, Estee Rebibo Demry, Allan H Young, K Kleine Schaars iD, Mario Juruena iD, Thomas G Schulze, Jaakko Kaprio iD, Psy-PGx Consortium, Roos van Westrhenen iD, Noam Shomron iD

Pharmaceuticals · 01.07.2026 · 19 (7) · 1028

DOI: 10.3390/ph19071028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 01.07.2026. Verfasst von Tehila Cohen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Human Genetics and Computational Medicine, Gray Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union, European Union’s Horizon 2020 research and innovation programme, Imperial College London’s Institutional Open Access Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Antidepressant treatment response is highly variable, and CYP2D6 metabolizer phenotype has been proposed as a contributor to this variability. It was examined whether CYP2D6 metabolizer phenotype is associated with real-world antidepressant treatment outcomes in a large population-based cohort.

Methods

Using genetic and longitudinal primary care prescription data from the UK Biobank, we evaluated associations between CYP2D6 metabolizer phenotype and prescription-based proxies of treatment outcomes, including discontinuation, switching, and side effects. Analyses were stratified by antidepressant and adjusted for demographic covariates.

Results

Among 26,957 individuals of European ancestry prescribed CYP2D6-metabolized antidepressants, reduced metabolic capacity was significantly associated with early discontinuation of paroxetine (N = 5718), venlafaxine (N = 2327), and mirtazapine (N = 3340). For paroxetine, poor metabolizers had higher odds of discontinuation compared with normal metabolizers and, among discontinuers, were more likely to stop immediately rather than later. Similar early discontinuation signals were observed for venlafaxine, with intermediate metabolizers showing increased risk. Mirtazapine also demonstrated increased odds of early discontinuation among poor metabolizers. No significant association was observed for fluoxetine. Associations with switching were limited, and no significant associations were detected for side effects.

Conclusions

CYP2D6 variation appears to primarily influence early antidepressant discontinuation within the first 30 days of treatment, particularly for paroxetine, venlafaxine, and mirtazapine, rather than treatment switching or side effects. These findings provide observational support relevant to drug-specific gene interactions and suggest a role for CYP2D6-guided prescribing in clinical practice, notably in the first 30 days of antidepressant treatment.

Schlagwörter

Stichwörter der Autor:innen

CYP2D6antidepressantscytochrome P450depressive disorderdrug metabolismpharmacogeneticstreatment discontinuation

Autor:innen und Institutionen

  • Human Genetics and Computational Medicine, Gray Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
  • Sagol School of Neuroscience, Tel Aviv University, Tel Aviv 6997801, Israel.
  • Institute of Psychiatry, Psychology & Neurosciences, King's College London, London WC2R 2LS, UK.
  • Division of Psychiatry, Imperial College London, London W12 0NN, UK.
  • Outpatient Clinic Pharmacogenetics, Parnassia Psychiatric Institute, 1062 HN Amsterdam, The Netherlands.
  • Centre for Human Drug Research, 2333 CL Leiden, The Netherlands.

ORCID-Profile: K Kleine Schaars, Mario Juruena, Jaakko Kaprio, Roos van Westrhenen, Noam Shomron

Förderung

  • European Union
  • European Union’s Horizon 2020 research and innovation programme
  • Imperial College London’s Institutional Open Access Programme

Zitieren

APA

Cohen, T., Rebibo Demry, E., Young, A. H., Kleine Schaars, K., Juruena, M., Schulze, T. G., Kaprio, J., Psy-PGx Consortium, van Westrhenen, R., & Shomron, N. (2026). CYP2D6 Metabolizer Phenotype Is Associated with Early Antidepressant Discontinuation in the UK Biobank. Pharmaceuticals, 19(7), 1028. https://doi.org/10.3390/ph19071028

Vancouver

Cohen T, Rebibo Demry E, Young AH, Kleine Schaars K, Juruena M, Schulze TG, et al. CYP2D6 Metabolizer Phenotype Is Associated with Early Antidepressant Discontinuation in the UK Biobank. Pharmaceuticals. 2026;19(7):1028. doi:10.3390/ph19071028

BibTeX
@article{Cohen2026,
  author = {Cohen, Tehila and Rebibo Demry, Estee and Young, Allan H and Kleine Schaars, K and Juruena, Mario and Schulze, Thomas G and Kaprio, Jaakko and Psy-PGx Consortium and van Westrhenen, Roos and Shomron, Noam},
  title = {CYP2D6 Metabolizer Phenotype Is Associated with Early Antidepressant Discontinuation in the UK Biobank},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {7},
  pages = {1028},
  doi = {10.3390/ph19071028}
}
Kostenlos starten →